Black Rock Inc. Glycomimetics Inc Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Glycomimetics Inc stock. As of the latest transaction made, Black Rock Inc. holds 732,567 shares of GLYC stock, worth $197,793. This represents 0.0% of its overall portfolio holdings.

Number of Shares

732,567

Previous 734,983 0.33%

Holding current value

$197,793

Previous $1.73 Million 26.7%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$2.55 - $3.49 $6,160 - $8,431	-2,416 Reduced 0.33%	732,567 $2.2 Million
Q4 2023 Feb 13, 2024	BUY	$1.13 - $2.54 $315 - $708	279 Added 0.04%	734,983 $1.73 Million
Q3 2023 Nov 13, 2023	SELL	$1.29 - $1.73 $63,469 - $85,117	-49,201 Reduced 6.28%	734,704 $1.1 Million
Q2 2023 Aug 11, 2023	BUY	$1.21 - $2.08 $163,337 - $280,779	134,990 Added 20.8%	783,905 $1.36 Million
Q1 2023 May 12, 2023	SELL	$1.25 - $4.05 $137,226 - $444,613	-109,781 Reduced 14.47%	648,915 $817,000

Q4 2022 Feb 13, 2023	SELL	$0.67 - $3.03 $4,816 - $21,782	-7,189 Reduced 0.94%	758,696 $2.3 Million
Q3 2022 Nov 14, 2022	SELL	$0.56 - $0.9 $1,370 - $2,203	-2,448 Reduced 0.32%	765,885 $423,000
Q2 2022 Aug 12, 2022	SELL	$0.54 - $1.15 $53,948 - $114,889	-99,904 Reduced 11.51%	768,333 $459,000
Q1 2022 May 12, 2022	SELL	$1.0 - $1.58 $4,621 - $7,301	-4,621 Reduced 0.53%	868,237 $990,000
Q4 2021 Feb 10, 2022	SELL	$1.44 - $2.14 $3,301 - $4,907	-2,293 Reduced 0.26%	872,858 $1.26 Million
Q3 2021 Nov 09, 2021	SELL	$1.8 - $2.39 $19,794 - $26,282	-10,997 Reduced 1.24%	875,151 $1.92 Million
Q2 2021 Aug 11, 2021	BUY	$2.16 - $3.18 $1.91 Million - $2.82 Million	886,148 New	886,148 $2.06 Million

Others Institutions Holding GLYC

# of Institutions

Shares Held

36.8M

Call Options Held

969K

Put Options Held

636K

View Full List

About GLYCOMIMETICS INC

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $14.2M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

More about GLYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account